Design and antileishmanial activity of amphotericin B-loaded stable Ionic Amphiphile Biovector formulations

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1597-1601

  Loiseau, P M ^a   Imbertie, L ^a   Bories, C ^a   Betbeder, D ^a   De Miguel, I ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; DIPALMITOYLPHOSPHATIDYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IONIC AMPHIPHILIC BIOVECTOR; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPIDS; MICE; MICE, INBRED BALB C; PHOSPHATIDYLGLYCEROLS; POLYSACCHARIDES;

EID: 0036239121     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1597-1601.2002     Document Type: Article

References (6)

1. Therapy in man
2. Liposomal amphotericin B in drug-resistant visceral leishmaniasis
3. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188
4. New Ionic Amphiphile Biovector™ as carrier of poor solubility drugs
5. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes